Please login to the form below

Halozyme Therapeutics

This page shows the latest Halozyme Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Halozyme to resume pancreatic cancer study

FDA says PEGPH20 trial can continue. There was relief for Halozyme Therapeutics after it was told it can resume a clinical study investigating a potential treatment for pancreatic cancer. ... With the trial now back underway, Halozyme said it intends to

Latest news

Halozyme halts pancreatic cancer trial

The biopharma company is investigating PEGPH20’s links to blood clot. Halozyme Therapeutics has paused a phase II trial of its investigational pancreatic cancer drug in order to assess the ... As for the fate of PEGPH20, Halozyme's CEO Dr Helen Torley
Baxter re-files HyQvia for immunodeficiency in US

HyQvia - which uses delivery technology developed by Halozyme Therapeutics - is a combination of human normal immunoglobulin (IG) and recombinant human hyaluronidase which can be delivered by subcutaneous injection every three to ... Meanwhile, for
Roche wins EU approval for injectable Herceptin

Roche developed subcutaneous Herceptin using recombinant human hyaluronidase technology developed by US-based biopharma company Halozyme Therapeutics.
Drug delivery

Halozyme receives $9m upfront and up to $54m in development and regulatory milestones. ... Commercialisation. 134. Halozyme Therapeutics/Intrexon Corp. rHuPH20 enzyme drug delivery. technology for COPD and genetic emphysema.
New leadership for Halozyme

Halozyme Therapeutics, the San Diego-based enzyme therapy developer that in October realigned its research priorities and cut its workforce by 25 per cent, has appointed Gregory I Frost to serve ... Halozyme Therapeutics, whose partners include Roche and

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Latest Intelligence

Pharma deals in June 2015

Acquisition - company. 1, 470. Halozyme Therapeutics/ AbbVie. ENHANZE platform technology to improve sc delivery (up to 9 targets). ... NewCo formation, collaboration. 760. Unum Therapeutics/ Seattle Genetics. Antibody-coupled T-cell receptor technology
Deal Watch table for December 2014

Expansion of collaboration/ amended agreement. 675. Halozyme Therapeutics / J&J. ENHANZE rHuPH20 delivery technology for up to 5 targets. ... Licence - amended agreement. †300. Spark Therapeutics / Pfizer. Multiple haemophilia B gene therapy products
Pharma deals during December 2014

Switching to drug delivery technologies, J&J/Janssen entered into a global licence with Halozyme Therapeutics to access Halozyme's ENHANZE technology, which is designed to enable subcutaneous administration of injectable ... Subcutaneous formulations of

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

Amgen veteran Kurt Gustafson joins Spectrum as CFO

He joins Spectrum from fellow US biotech Halozyme Therapeutics, where he served as VP and chief financial officer.